Catalyst MedTech Launches "Connect" Program to Expand Access to Advanced Imaging; Announces Initial Partnership with Algernon Pharmaceuticals
MWN-AI** Summary
Catalyst MedTech has announced the launch of its "Connect" program, aimed at expanding access to advanced diagnostic imaging and treatments for patients. This initiative utilizes Catalyst's dual business structure—Equipment Solutions and Clinical Solutions—to foster collaborations that allow innovative medical technologies to reach the patients who need them most.
The program's inaugural partnership is with Algernon Pharmaceuticals, a Canadian healthcare firm focused on enhancing access to Optimized Brain PET imaging in the U.S. Together, the two companies aim to establish a dedicated network of neuroimaging clinics for early detection of Alzheimer's disease. This partnership highlights the commitment to leverage Catalyst's advanced imaging solutions, notably the CareMiBrain™ system, which integrates with the NeuroQ® advanced quantitative workstation to provide precise and scalable diagnostics in neurology.
Catalyst's CEO, Martin B. Shirley, emphasized the importance of bridging vision and execution, stating that the Connect program serves to complete the journey for partners striving to make an impact in healthcare sectors such as neurology and cardiology. This support is crucial as millions are at risk for neurodegenerative diseases, making early and confident diagnoses essential.
Christopher J. Moreau, CEO of Algernon Pharmaceuticals, expressed enthusiasm for the collaboration, stressing that their shared mission aligns to significantly improve diagnosis and treatment for Alzheimer's and related conditions.
Catalyst MedTech positions itself as a leading influence in advanced imaging, ensuring that modern breakthroughs translate into enhanced patient care. The company functions as a nationwide provider of nuclear medicine and molecular imaging solutions, striving to deliver comprehensive diagnostic access and value for healthcare providers and patients alike.
MWN-AI** Analysis
Catalyst MedTech's recent launch of the "Connect" program signifies a significant advancement in the landscape of advanced medical imaging, particularly in the realm of early Alzheimer's detection. By collaborating with Algernon Pharmaceuticals, Catalyst aims to create a dedicated network of neuroimaging clinics across the U.S. This strategic initiative demonstrates Catalyst's commitment to enhancing patient access to cutting-edge diagnostic tools, specifically their Optimized Brain PET and CareMiBrain™ systems.
For investors, this partnership presents a unique opportunity to align with a company at the forefront of addressing critical healthcare needs. The demographic trends indicate an increasing prevalence of Alzheimer's, making early detection paramount. As such, companies that can successfully intersect innovation with patient care stand to benefit considerably from growing demand.
Catalyst MedTech's dual focus on Equipment Solutions and Clinical Solutions positions it as a comprehensive provider in the imaging space. Its ISO-certified service capabilities further enhance its competitive edge, ensuring that healthcare providers can rely on exceptional service and support across a multi-vendor equipment portfolio.
Algernon Pharmaceuticals' focus on developing a specialized network for the early-stage detection of neurodegenerative diseases aligns well with current healthcare trends that prioritize preventative medicine. This partnership could lead to higher adoption rates of advanced imaging solutions, potentially boosting revenue streams for both companies.
Given these dynamics, investors should closely monitor Catalyst MedTech's execution of the Connect program, particularly its ability to scale operations within the U.S. market and its impact on healthcare providers seeking advanced imaging solutions. Long-term growth prospects appear promising given the rising demand for early diagnostic methodologies in neurology. As always, investors should consider both market conditions and the innovation pipeline as they evaluate potential stakes in Catalyst MedTech and Algernon Pharmaceuticals.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
PITTSBURGH , Oct. 7, 2025 /PRNewswire/ -- Catalyst MedTech today announced the launch of its new Connect program, an initiative that brings together collaborators seeking to advance patient care with the access required to make it possible. Connect leverages Catalyst's unique dual business structure—Equipment Solutions and Clinical Solutions—to deliver customizable pathways that expand access to diagnostic imaging and treatment. Connect ensures innovation has a pathway to reach the patients it was built for.
As part of the launch, Catalyst also announced its first Connect partnership with Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian publicly traded healthcare company, focused on expanding access to Optimized Brain PET imaging in the United States . By enrolling as a Connect Partner, Algernon is moving forward with its plan to establish the first dedicated network of neuroimaging medical clinics in the United States for the early-stage detection of Alzheimer's. Catalyst is powering this vision with a tailored mix of equipment, service, and support—featuring the Optimized Brain PET solution that combines CareMiBrain™ with the NeuroQ® advanced quantitative workstation.
"The vision of Connect is to help finish the story for our partners," said Martin B Shirley, CEO & President of Catalyst MedTech. "Many companies want to make an impact in a specific space — whether in neurology, cardiology, or beyond. Catalyst is the connector that makes those ambitions real by providing the access, expertise, and solutions needed to bridge vision and execution. We connect the dots directly to the patients for their benefit."
With millions at risk for Alzheimer's and related conditions, dedicated Brain PET is increasingly recognized as the standard for earlier, more confident diagnosis. The optimized CareMiBrain™ system, exclusively distributed in the U.S. by Catalyst MedTech sets a new benchmark in neurologic imaging. The complete system combines ultra-high resolution imaging within a compact, patient-friendly design with an advanced quantitative neurologic workstation — delivering diagnostic precision and practical scalability for neurology practices, imaging centers, and hospitals.
"We are very excited to be working with Catalyst MedTech to accelerate access to Brain PET in the U.S.," said Christopher J. Moreau , CEO of Algernon Pharmaceuticals Inc. "Catalyst's ability to connect the dots between innovation, access, and patient care perfectly aligns with our mission to establish a network of advanced neuroimaging clinics. Together, we can make a meaningful difference in how patients with Alzheimer's and other neurodegenerative conditions are diagnosed and treated."
Catalyst MedTech continues to position itself as the thought leader and connector in advanced imaging. By creating pathways for adoption, Catalyst MedTech ensures that breakthroughs in imaging translate into better care, earlier answers, and improved patient outcomes.
About Catalyst MedTech
Catalyst MedTech is a nationwide provider of nuclear medicine, molecular imaging, and CT solutions. Our purpose is simple but powerful: to deliver value and access through advanced diagnostic imaging and related therapies—so patients get the care and treatments they need.
With OEM-trained service teams, clinical expertise, and a multi-vendor equipment portfolio, we support providers in cardiology, neurology, and beyond. As an OEM that is also the largest NM/MI independent ISO-certified service provider in the U.S., Catalyst MedTech is helping healthcare organizations achieve earlier answers, stronger confidence, and better outcomes—seeing what's possible in diagnostic imaging today and tomorrow.
Visit www.catalystmedtech.com for more information.
Media Contact: Kate Kinsell , kkinsell@catalystmedtech.co m
About Algernon Pharmaceuticals
Algernon Pharmaceuticals (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is a Canadian healthcare company focused on the provision of brain specific PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer's disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. Algernon is also the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury. The Company also owns a 20% equity position in Seyltx, a private U.S. based drug development company advancing a chronic cough drug called Ifenprodil.
Visit www.algernonpharmaceuticals.com for more information.
SOURCE Catalyst MedTech
FAQ**
How will Catalyst MedTech's Connect program specifically enhance access to advanced imaging technologies like the Optimized Brain PET solution provided in partnership with Algernon Pharmaceuticals Inc - Class A AGNPF?
What are the expected outcomes and benefits for patients with Alzheimer's as a result of establishing this dedicated network of neuroimaging clinics by Algernon Pharmaceuticals Inc - Class A AGNPF in collaboration with Catalyst MedTech's Connect program?
What measures will Catalyst MedTech take to ensure the successful integration of their equipment solutions with the clinical objectives of Algernon Pharmaceuticals Inc - Class A AGNPF in the new network of neuroimaging clinics?
How does Catalyst MedTech plan to leverage its dual business structure to support future partnerships beyond Algernon Pharmaceuticals Inc - Class A AGNPF within the Connect program, particularly in other medical fields like cardiology?
**MWN-AI FAQ is based on asking OpenAI questions about Algernon Pharmaceuticals Inc - Class A (OTC: AGNPF).
NASDAQ: AGNPF
AGNPF Trading
-13.14% G/L:
$0.0271 Last:
240 Volume:
$0.02714 Open:
